/ /

  • linkedin
  • Increase Font
  • Sharebar

    Changing the game in treatment of acute pseudophakic CME

    Bromfenac/delivery vehicle yields high intraocular concentration, more efficacious response

    As a retinal surgeon, I am constantly evaluating new technologies and medications to help give patients the best possible visual outcomes.

    Pseudophakic cystoid macular edema (CME), also known as Irvine-Gass syndrome, is one of the most common causes of visual loss after cataract surgery.1

    In 1953, Irvine described a CME that specifically resulted after cataract surgery.2

    In addition, Gass and Norton also extensively studied the disease with fluorescein angiography.3,4

    Phacoemulsification and small-incision cataract surgery have significantly reduced the incidence of pseudophakic CME, but because cataract surgery is the most commonly performed surgery in the United States, pseudophakic CME remains a commonly encountered morbidity.5,6

    The approximate incidence of clinical CME after small-incision phacoemulsification is estimated to be between 0.1% to 2.35%.7,8

    Previous studies have examined Medicare patients who underwent modern cataract surgery and determined that the total ophthalmic payments were 47% higher for those who developed pseudophakic CME compared with those who did not, thus representing a significant cost to the healthcare system.9

     

    Topical NSAID

     

    Bromfenac ophthalmic solution 0.075% (BromSite, Sun Ophthalmics) is a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.10 Bromfenac is the active molecule that is designed for improved corneal penetration given the bromine component which allows for enhanced lipophilicity and ocular tissue penetration.

    However, the key feature of this medication is the delivery system (DuraSite) that allows the delivery vehicle to be more viscous and mucoadhesive—thus increasing retention time on the ocular surface and allowing for a higher intraocular concentration of bromfenac. This higher intraocular concentration is critical to treat diseases of the posterior segment, including Irvine-Gass CME.

    Since the FDA approval and launch of the product in 2016, I have taken the opportunity to utilize it in my acute CME patients and have observed tremendously successful results.

    Posterior segment

    Joshua Mali, MD
    Joshua Mali, MD, is a vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results